Hospital Pharmacy - June 2017 - 411
Shanbhag et al
A Naranjo Adverse Drug Reaction Probability Scale score
of 9 suggests lenalidomide was a highly probable cause of
this patient's presentation.
Conclusion
DRESS syndrome is fatal in approximately 10% of patients
and should be considered a rare but potential complication
with lenalidomide.24 Practitioners could have easily missed
lenalidomide as the highly probable culprit medication in our
patient as sepsis secondary to skin or soft tissue infection
was probable. Hence, with the increasing use of oral lenalidomide in hematological disorders, practitioners need to be
aware of this adverse reaction, hold the medication if the
diagnosis is being considered, and complete a thorough
patient work-up while providing supportive care.
Authors' Note
Presentation of this content was provided at the Society of Critical
Care Medicine 46th Annual Congress in Honolulu, Hawaii.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
References
1. Choudhary S, McLeod M, Torchia D, Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 2013;6(6):31-37.
2. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update.
Dermatology. 2003;206(4):353-356.
3. Roujeau J-C. Treatment of severe drug eruptions. J Dermatol.
1999;26(11):718-722.
4. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to
drugs. N Engl J Med. 1994;331(19):1272-1285.
5. Callot V, Roujeau JC, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol. 1996;132(11):1315-1321.
6. Sullivan JR, Shear NH. The drug hypersensitivity syndrome:
what is the pathogenesis? Arch Dermatol. 2001;137(3):357-364.
7. Santiago F, Gonçalo M, Vieira R, Coelho S, Figueiredo A.
Epicutaneous patch testing in drug hypersensitivity syndrome
(DRESS). Contact Dermatitis. 2010;62(1):47-53.
8. Chiou C-C, Yang L-C, Hung S-I, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic
symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol
Venereol. 2008;22(9):1044-1049.
411
9. Kocaoglu C, Cilasun C, Solak ES, Kurtipek GS, Arslan S.
Successful treatment of antiepileptic drug-induced DRESS
syndrome with pulse methylprednisolone. Case Rep Pediatr.
2013;2013:1-4.
10. Picard D, Janela B, Descamps V, et al. Drug reaction
with eosinophilia and systemic symptoms (DRESS): a
multiorgan antiviral T cell response. Sci Transl Med.
2010;2(46):46ra62.
11. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine
modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J
Immunol. 1999;163(1):380-386.
12. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210-216.
13. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer.
2002;87(10):1166-1172.
14. Anderson KC. Lenalidomide and thalidomide: mechanisms of
action-similarities and differences. Semin Hematol. 2005;42(4)
(suppl 4):S3-8.
15. Nardone B, Wu S, Garden BC, et al. Risk of rash associated
with lenalidomide in cancer patients: a systematic review of the
literature and meta-analysis. Clin Lymphoma Myeloma Leuk.
2013;13:424-429.
16. Ferrajoli A, Lee B-N, Schlette EJ, et al. Lenalidomide
induces complete and partial remissions in patients with
relapsed and refractory chronic lymphocytic leukemia. Blood.
2008;111(11):5291-5297.
17. FDA Drug Safety Newsletter: Postmarketing reviews. Summer
2008;1(4):41-44.
18. Castaneda CP, Brandenburg NA, Bwire R, Burton GH, Zeldis
JB. Erythema multiforme/Stevens-Johnson syndrome/toxic
epidermal necrolysis in lenalidomide-treated patients. J Clin
Oncol. 2009;27(1):156-157.
19. Shaaban H, Layne T, Guron G. A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute
interstitial nephritis secondary to lenalidomide. J Oncol Pharm
Pract. 2013;20(4):302-304.
20. Vlachopanos G, Kokkona A, Zerva A, et al. Atypical DRESS
syndrome induced by lenalidomide in chronic hemodialysis. J
Clin Exp Pathol. 2016;6(3):1-3.
21. Foti C, Antelmi A, Mazzocca A, et al. Drug reaction with
eosinophilia and systemic symptoms caused by lenalidomide.
Eur J Dermatol. 2012;22(6):799-800.
22. Lerch E, Györik S, Feilchenfeldt J, Mazzucchelli L, Quadri F.
A case of lenalidomide-induced hypersensitivity pneumonitis.
Onkologie. 2010;33(5):249-252.
23. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol
Ther. 1981;30(2):239-245.
24. Walsh SA, Creamer D. Drug reaction with eosinophilia and
systemic symptoms (DRESS): a clinical update and review of
current thinking. Clin Exp Dermatol. 2011;36(1):6-11.
Table of Contents for the Digital Edition of Hospital Pharmacy - June 2017
Formal Leadership: Thrilling (and Scary) Like a Roller Coaster Ride
ISMP Medication Error Report Analysis
Cancer Chemotherapy Update: Bevacizumab, Etoposide, and Cisplatin Regimen for Refractory Brain Metastases
Formulary Drug Reviews: Plecanatide
Calcitonin Gene-Related Peptide Receptor Antagonists for Migraine Prophylaxis: A Review of a Drug Class or Therapeutic Class in a Late Stage of Clinical Development
Highly Probable Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Lenalidomide
Significant Published Articles for Pharmacy Nutrition Support Practice in 2016
Financial Effect of a Drug Distribution Model Change on a Health System
Limited Influence of Excipients in Extemporaneous Compounded Suspensions
Improved Outcomes and Cost Savings Associated With Pharmacist Presence in the Emergency Department
Patients Given Take Home Medications Instead of Paper Prescriptions Are More Likely to Return to Emergency Department
Hospital Pharmacy - June 2017 - 381
Hospital Pharmacy - June 2017 - 382
Hospital Pharmacy - June 2017 - 383
Hospital Pharmacy - June 2017 - 384
Hospital Pharmacy - June 2017 - 385
Hospital Pharmacy - June 2017 - 386
Hospital Pharmacy - June 2017 - 387
Hospital Pharmacy - June 2017 - Formal Leadership: Thrilling (and Scary) Like a Roller Coaster Ride
Hospital Pharmacy - June 2017 - 389
Hospital Pharmacy - June 2017 - ISMP Medication Error Report Analysis
Hospital Pharmacy - June 2017 - 391
Hospital Pharmacy - June 2017 - 392
Hospital Pharmacy - June 2017 - 393
Hospital Pharmacy - June 2017 - Cancer Chemotherapy Update: Bevacizumab, Etoposide, and Cisplatin Regimen for Refractory Brain Metastases
Hospital Pharmacy - June 2017 - 395
Hospital Pharmacy - June 2017 - 396
Hospital Pharmacy - June 2017 - 397
Hospital Pharmacy - June 2017 - 398
Hospital Pharmacy - June 2017 - 399
Hospital Pharmacy - June 2017 - Formulary Drug Reviews: Plecanatide
Hospital Pharmacy - June 2017 - 401
Hospital Pharmacy - June 2017 - 402
Hospital Pharmacy - June 2017 - 403
Hospital Pharmacy - June 2017 - 404
Hospital Pharmacy - June 2017 - 405
Hospital Pharmacy - June 2017 - Calcitonin Gene-Related Peptide Receptor Antagonists for Migraine Prophylaxis: A Review of a Drug Class or Therapeutic Class in a Late Stage of Clinical Development
Hospital Pharmacy - June 2017 - 407
Hospital Pharmacy - June 2017 - Highly Probable Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Lenalidomide
Hospital Pharmacy - June 2017 - 409
Hospital Pharmacy - June 2017 - 410
Hospital Pharmacy - June 2017 - 411
Hospital Pharmacy - June 2017 - Significant Published Articles for Pharmacy Nutrition Support Practice in 2016
Hospital Pharmacy - June 2017 - 413
Hospital Pharmacy - June 2017 - 414
Hospital Pharmacy - June 2017 - 415
Hospital Pharmacy - June 2017 - 416
Hospital Pharmacy - June 2017 - 417
Hospital Pharmacy - June 2017 - 418
Hospital Pharmacy - June 2017 - 419
Hospital Pharmacy - June 2017 - 420
Hospital Pharmacy - June 2017 - 421
Hospital Pharmacy - June 2017 - Financial Effect of a Drug Distribution Model Change on a Health System
Hospital Pharmacy - June 2017 - 423
Hospital Pharmacy - June 2017 - 424
Hospital Pharmacy - June 2017 - 425
Hospital Pharmacy - June 2017 - 426
Hospital Pharmacy - June 2017 - 427
Hospital Pharmacy - June 2017 - Limited Influence of Excipients in Extemporaneous Compounded Suspensions
Hospital Pharmacy - June 2017 - 429
Hospital Pharmacy - June 2017 - 430
Hospital Pharmacy - June 2017 - 431
Hospital Pharmacy - June 2017 - 432
Hospital Pharmacy - June 2017 - Improved Outcomes and Cost Savings Associated With Pharmacist Presence in the Emergency Department
Hospital Pharmacy - June 2017 - 434
Hospital Pharmacy - June 2017 - 435
Hospital Pharmacy - June 2017 - 436
Hospital Pharmacy - June 2017 - 437
Hospital Pharmacy - June 2017 - Patients Given Take Home Medications Instead of Paper Prescriptions Are More Likely to Return to Emergency Department
Hospital Pharmacy - June 2017 - 439
Hospital Pharmacy - June 2017 - 440
Hospital Pharmacy - June 2017 - 441
Hospital Pharmacy - June 2017 - 442
Hospital Pharmacy - June 2017 - 443
Hospital Pharmacy - June 2017 - 444
Hospital Pharmacy - June 2017 - 445
Hospital Pharmacy - June 2017 - 446
Hospital Pharmacy - June 2017 - 447
Hospital Pharmacy - June 2017 - 448
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2020
https://www.nxtbook.com/nxtbooks/sage/psychologicalscience_demo
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2020
https://www.nxtbook.com/nxtbooks/sage/fai_202009
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_august2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2019
https://www.nxtbook.com/nxtbooks/sage/fai_201909
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_july2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2019
https://www.nxtbook.com/nxtbooks/sage/canadianpharmacistsjournal_05062019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2019
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201903
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2018
https://www.nxtbook.com/nxtbooks/sage/tec_20180810
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2018
https://www.nxtbook.com/nxtbooks/sage/fai_201807
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2018
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201803
https://www.nxtbook.com/nxtbooks/sage/slas_discovery_201712
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_november2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_september2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2017
https://www.nxtbook.com/nxtbooks/sage/fai_supplement_201709
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_may2017
https://www.nxtbook.com/nxtbooks/sage/fai_201706
https://www.nxtbook.com/nxtbooks/sage/fai_201607
https://www.nxtbookmedia.com